SGLT2 inhibitors in acute decompensated heart failure, what do we know?

SGLT2 inhibitors in acute decompensated heart failure, what do we know?

The current worldwide prevalence of heart failure is growing, while its combination with cardiovascular and other conditions determines a poor prognosis in these patients. Furthermore, acute decompensated heart failure is associated with a low survival rate mostly caused by target organ damage. The...

Full description

Bibliographic Details
Main Authors:	Anastasiya E. Lapteva, Svetlana N. Nasonova, Igor V. Zhirov, Sergey N. Tereshchenko
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2022-05-01
Series:	Терапевтический архив
Subjects:	chronic heart failure acute decompensated heart failure type 2 diabetes mellitus sglt2 inhibitors cardiovascular outcomes
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/108240/81793

Similar Items

Acute decompensation of heart failure: state of the problem
by: Igor V. Zhirov, et al.
Published: (2022-10-01)

Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
by: Anastasiya E. Poskakalova, et al.
Published: (2023-07-01)

Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure
by: I. V. Zhirov, et al.
Published: (2022-06-01)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
by: Panagiotis Theofilis, et al.
Published: (2023-02-01)

PATHOPHYSIOLOGY OF ACUTE HEART FAILURE. WHAT’S NEW?
by: S. N. Tereshchenko, et al.
Published: (2016-09-01)

IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
by: M. V. Lediakhova, et al.
Published: (2018-05-01)

Strategy of selecting the scales of risk, prognosis, and disease severity in patients with acute decompensated heart failure
by: A. G. Arutyunov
Published: (2013-04-01)

Risk factors for acute decompensated heart failure in type 2 diabetes patients
by: N. A. Koziolova, et al.
Published: (2020-05-01)

Aquaretics Use in Acute Decompensated Heart Failure (ADHF) Patients: A Literature Review
by: Norman Sukmadi, et al.
Published: (2022-07-01)

Systems of care for ambulatory management of decompensated heart failure
by: Narotham Badrish, et al.
Published: (2024-02-01)

Epidemiology of acute decompensated heart failure in India : The AFAR study (Acute failure registry study)
by: Sandeep Seth, et al.
Published: (2015-01-01)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022-08-01)

Predictors of community-acquired pneumonia in patients with acute decompensated heart failure: the results of the analysis of the hospital sample EPOHA-D-CHF
by: D.S. Polyakov, et al.
Published: (2018-04-01)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
by: Carolyn S. P. Lam, et al.
Published: (2019-10-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial
by: Yu. M. Lopatin, et al.
Published: (2022-04-01)

Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
by: Alexander A. Berezin, et al.
Published: (2023-03-01)

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
by: Noor Ul Amin, et al.
Published: (2022-11-01)

SERELAXIN IN THE STRATEGY OF MANAGEMENT THE PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: FROM DECREASING OF SYMPTOMS TO THE IMPROVEMENT OF SURVIVAL
by: I. V. Zhirov, et al.
Published: (2015-09-01)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
by: Hai‐Bin Chen, et al.
Published: (2023-04-01)

Risk stratification in heart failure decompensation in the community: HEFESTOS score
by: José‐María Verdu‐Rotellar, et al.
Published: (2022-02-01)

The Importance of Hyperthyroid Screening in Acute Decompensated Heart Failure with Persistent Tachycardia Despite Optimal Decongestion: A Case Report
by: Matthew Aldo Wijayanto, et al.
Published: (2023-05-01)

SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
by: Inês Aguiar-Neves, et al.
Published: (2023-01-01)

The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
by: Panagiotis Stachteas, et al.
Published: (2024-03-01)

Sodium glucose co-transporter 2 inhibitors in heart failure therapy
by: Yüksel Çavuşoğlu, et al.
Published: (2020-04-01)

Construction of risk prediction model for hyponatremia in patients with acute decompensated heart failure
by: Huanhuan Gong, et al.
Published: (2023-10-01)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023-03-01)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023-03-01)

Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View
by: Silvia Prosperi, et al.
Published: (2023-09-01)

Prognostic Effect of a Novel Simply Calculated Nutritional Index in Acute Decompensated Heart Failure
by: Sayaki Ishiwata, et al.
Published: (2020-10-01)

Rationale, methodology, and design of Indian College of Cardiology National Heart Failure Registry
by: P B Jayagopal, et al.
Published: (2020-01-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01)

Long-term impact of home-based monitoring after an admission for acute decompensated heart failure: a systematic review and meta-analysis of randomised controlled trialsResearch in context
by: Mariana R.C. Clemente, et al.
Published: (2024-05-01)

Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study
by: Maximilian J. Steinhardt, et al.
Published: (2024-01-01)

Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment
by: Siqi Wang, et al.
Published: (2021-07-01)

Identifying Candidate Protein Markers of Acute Kidney Injury in Acute Decompensated Heart Failure
by: Evelyn M. Templeton, et al.
Published: (2022-01-01)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
by: Asmaa Elrakaybi, et al.
Published: (2022-10-01)

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
by: Clipper F. Young, et al.
Published: (2023-09-01)

Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis
by: Razan Al Namat, et al.
Published: (2023-12-01)

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
by: Tomoaki Okada, et al.
Published: (2023-04-01)